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Overline: Neurodegenerative Disease 
 
Single Sentence Summary: 
We can now create an unprecedented set of mouse models for understanding neurodegeneration 
and we need to carefully consider which model best fits our research question and how to learn 
from the variability within and between studies. 
 
Abstract 
Many mutant mouse strains have been developed to investigate neurodegenerative diseases, but 
variability among mouse studies has led to questioning of the value of these mouse models. Here, 
we appraise various mouse models for dissecting neurodegenerative mechanisms and emphasise 
the importance of asking appropriate scientific questions and understanding variability among and 
within studies.  In therapeutics research, we suggest that not embracing this variability in mouse 
models may contribute to translational failure in human patients.   
 
 
INTRODUCTION 
Neurodegenerative diseases are common, largely untreatable and certainly incurable, and create a 
huge health and social burden worldwide. For example, in 2018, more than 50 million people 
worldwide had dementia of which ~70% was caused by Alzheimer’s disease (AD) with an overall cost 
of $1 trillion(1). Currently ~66% of those with dementia live in low or middle income countries (1). For 
neurodegenerative movement disorders, for example, ~10 million people worldwide currently suffer 
from Parkinson’s disease (PD) (2). These diseases are not necessarily illnesses of older age: type 1 
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spinal muscular atrophy (SMA) is the biggest single genetic killer of children under 5 years of age, 
affecting up to 1 in 10,000 newborns. A typical mid-life onset disorder such as amyotrophic lateral 
sclerosis (ALS) has been described in children as young as 11 years of age (3). As with many other 
human diseases, each manifestation of neurodegeneration is likely to vary from person to person and 
will probably require a tailored combination of treatments for different patient subgroups. 
 For decades, mice have been the mammal of choice for modeling neurodegenerative diseases 
because of our ability to exquisitely manipulate their DNA.  However, few genetically modified mouse 
models fully recapitulate the human condition or have yet been instrumental in delivering treatments 
for neurodegeneration. This is leading some researchers to doubt the utility of mouse models in the 
hunt for therapies and to turn instead to alternative approaches, such as induced pluripotent stem 
cells (iPSCs) derived from fibroblasts or other cells of  patients. However, much of the uncertainty 
regarding mouse models stems from expecting each model to completely mimic human disease. Yet 
mice only live for two years or so and exhibit differences from humans at all levels, from the genome 
through to neuroanatomy, the immune system and behaviour.  Uncertainty also arises from the 
apparent lack of reproducibility of results between laboratories. Indeed, confounding variability is 
evident not only across studies and across laboratories but also even within cohorts of the same 
genotype being studied within one laboratory.   
 Clearly, a multiplicity of models, including genetically modified mice and 3D cellular systems, 
is required to understand neurodegenerative diseases. For example, human iPSCs provide cellular  
models and robust in vitro readouts that could be used for high throughput analysis such as drug 
screens, which are not feasible in mice. However, mouse models remain essential because they enable 
us to take a holistic approach over the lifespan of an animal, giving us access to in vivo systemic 
interactions -- between cell types (for example, glia and neurons), tissues (for example, muscle and 
neurons), and whole animal systems (for example, the immune system and the nervous system). They 
also provide access to developmental, metabolic  and behavioural outcomes over the natural history 
of a disease. In particular, as many of the symptoms in human patients we are trying to treat are 
behavioral (for example, memory impairments, deficits in cognition), it is essential to understand how 
molecular, cellular and circuit changes manifest as functional changes in the behavior of the organism.  
Mice also allow us to model environmental effects and individual responses over a lifetime in a way 
that is impossible in cellular systems.  
 Here, we argue that we need to acknowledge the differences between mice and humans and, 
most importantly, to tailor each mouse model to the research question being asked, in order to 
elucidate mechanisms of neurodegeneration. We ask why mice with the same genetic mutation have 
divergent phenotypes in pathological and behavioral sequelae and how we can turn this to our  
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advantage. What we have hitherto seen as a problem and a lack of reproducibility, we now suggest 
may be an important opportunity for understanding gene interactions and interactions of genes with 
the environment, which may also underlie the variability of disease phenotypes observed in humans. 
Finally, we discuss briefly the failure to translate mechanistic findings in mice to therapies in humans, 
and suggest that this reflects the large diversity in the human clinical population that is currently not 
understood, nor captured in mouse studies. Embracing and understanding such variability in animal 
models may therefore be an essential step in the translational process.  
 
 
MICE AND HUMANS ARE DIFFERENT 
Despite the remarkable similarities between us, mice are not mini-humans and humans are not large 
mice. There are species-specific differences in every aspect of our biology, and these can be extremely 
helpful for highlighting key issues in human neurodegeneration.   
 At the genome level, ~90% of mouse and human DNA falls into regions of conserved synteny, 
distributed between the 46 human chromosome pairs and the 40 mouse chromosome pairs. Both 
species have similar numbers of protein coding genes, but roughly 1% of mouse genes appear to have 
no human equivalent and vice versa (4). These genomic differences can be an issue for mouse models. 
For example, approximately 1 in 800 babies are born with trisomy of human chromosome 21 (Hsa21), 
resulting in Down’s syndrome, which gives a greatly increased risk for early onset AD (5).  The long 
arm of Hsa21 has three regions of conserved homology with mouse chromosomes 10, 16, 17 (Mmu10, 
16, 17), and partial trisomies of these chromosomes have been used to model Down’s syndrome (6-
8) (6) (Figure 1).  However, four Hsa21 protein-coding genes appear to be absent in the mouse 
genome, and at least four mouse genes found in the regions of homology seem absent in humans (9), 
so mouse partial trisomies cannot fully model human trisomy 21. The Tc1 mouse model, which carries 
a partial copy of Hsa21, partly overcomes this issue, but human gene regulation and protein 
interactions may not be the same in a mouse cellular environment and this chromosome is lost 
stochastically from mouse cells (, for example, only ~70% of Tc1 mouse brain nuclei contain Hsa21) 
(7). No mouse can faithfully model Down’s syndrome, but analysis of phenotypes across a variety of 
mouse models of this disease has been valuable for teasing apart the complex biology of this human 
chromosomal disorder, providing we take into account the characteristics of each model and ask 
specific questions about refined aspects of the syndrome that can be addressed in these models (6, 
10).   
 Gene copy number may differ between humans and mice.  For example, humans have one 
copy of the SMN1 (survival motor neuron 1) gene and up to 4 copies of SMN2, which are paralogs that 
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lie within a duplicated region on chromosome 5. SMN2 has a single base pair difference from SMN1 
that results in alternative splicing such that only up to 20% of SMN2 transcripts encode functional 
protein. Mutations in SMN1 result in SMA, a neurodegenerative disease in which the lower motor 
neurons gradually die, and the rate of death is inversely related to the amount of functional SMN2. In 
the most severe form of the disease, children die before the age of four.  Mice have been essential for 
studying SMA, but the mouse has only one Smn gene. Heterozygous Smn mice carrying one knocked 
out allele and one wildtype allele are fully viable, whereas homozygous null mutant mice die early in 
embryogenesis (11).  Importantly, SMA has been modeled successfully by placing human SMN2 into 
Smn null mice (11). Now, a range of genetically different SMA mouse models exists, each carrying 
different patient mutations. Alternatively, some SMA mouse models carry an Smn gene that is 
mutated to resemble human SMN2. Each model has different advantages and disadvantages, such as 
reduced disease severity but a longer time in which to study disease processes (11). These models, 
including conditional mutant mice, have helped to dissect the timing of neuronal loss and to identify 
which neuronal populations are at risk. Furthermore, these mouse models have been critical for the 
development of therapies both conventional and genetic (11, 12).  These include the novel adeno-
associated virus gene therapy approach, now with FDA approval for a Phase 2 clinical trial, and the  
antisense oligo drug Spinraza which in 2016 was approved by the FDA as the first therapy for SMA 
(13). 
 With respect to gene expression, the ENCODE project has examined regulatory regions of 
mouse and human genomes in multiple tissues and cell types, and has demonstrated transcript 
profiles of a large number of human and mouse genes. The ENCODE project has revealed that much 
of the cis-regulatory landscape, including DNAse1 hypersensitive sites, are different between the two 
species (14-17). Mouse and human also have different splice variants, and humans produce a greater 
number of splice isoforms (average of 3.4 isoforms per gene) compared to mice (2.4 isoforms per 
gene) (18). Splice isoform differences are particularly important in diseases such as the most common 
genetic form of frontotemporal dementia (FTD) (19), which is caused by mutations in the MAPT 
(microtubule-associated protein tau) gene that encodes the protein TAU. Transgenic mice have been 
made using human MAPT cDNAs and these have been helpful for pinning down mechanism but mostly 
cannot address the abnormalities found in FTD that are caused by aberrant TAU splice isoform ratios. 
Now, however, mice with the complete human MAPT genomic region exist and these animals carry 
the various human TAU splice variants. Importantly for developing therapies, such mice respond to 
antisense oligonucleotide treatment by switching isoforms, thus giving insight into tauopathies and 
new models for developing therapies for FTD (20).   
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 Non-protein coding DNA may, or may not, be well-conserved between human and mouse; for 
example, osteocrin is an activity dependent secreted factor that is induced by membrane 
depolorisation in human, but not mouse neurons – because a primate specific enhancer has 
repurposed the expression of this gene which is non-neuronal in mouse (21). Mouse non-coding RNAs 
largely diverge in sequence from those of humans (22). Mutations in non-coding regions can be 
causative for neurodegeneration. Examples include the intronic mutations arising from primate 
specific repeats in the TAF1 gene that results in X-linked Parkinsonism Dystonia or in the Fukutin gene 
that leads to Fukuyama muscular dystrophy in humans (23, 24) or the tRNA mutation that can lead to 
neurodegeneration in the cortex, cerebellum and hippocampus in mice (25).  Cryptic or skiptic DNA 
elements may be associated with disease in humans but not exist in mice, such as the cryptic 
polyadenylation site in STATHMIN2 (a neuronal growth associated factor) that is present in sporadic 
and some genetic forms of ALS (26) . Non-coding changes also modulate disease outcomes: for 
example, by 2017 more than 3,000 different genome-wide association studies (GWAS) had reported 
>30,000 SNP-disease associations, the vast majority of which lie in non-coding regions (27), indicating 
the importance of gene regulation in disease, including neurodegenerative disease  (25, 28). 
 
Surprisingly, small differences in human and mouse amino acid sequences can have large effects on 
phenotype. Humans with three copies of the wildtype APP gene encoding amyloid precursor protein 
succumb to early onset AD, whereas three copies of wildtype mouse App does not lead to similar 
amyloid deposition in mice (5). Human and mouse APP are highly homologous but the 17 amino acid 
differences between them include three key residues that affect how APP protein forms amyloid 
deposits, and this may in part explain why human and mouse respond differently to having three 
‘doses’ of the wildtype APP gene (29). Studying these differences may help to shed light on how the 
primary amino acid sequence of APP affects amyloid deposition. Similarly, human and mouse 
superoxide dismutase 1 (SOD1) proteins have a few key amino acid differences, likely making the 
human protein more prone to aggregation than the mouse equivalent (30).  The SOD1D83G mutation 
causes autosomal dominant ALS in humans, but in mice the picture is very different. A mouse with the 
identical nucleotide and amino acid mutation (Sod1D83G) only exhibits progressive motor neuron loss 
when homozygous; such a mouse shows only mild upper motor neuron loss (~20% by 29 weeks of 
age) and a similar loss (23%) of lower motor neurons by 15 weeks of age. Remarkably, after these time 
points motor neuron loss stops and motor neuron numbers remain stable for at least a year, although 
accompanied by a severe peripheral neuropathy (31). Dissecting the phenotype of the Sod1D83G mouse 
has revealed that motor neuron axonal degeneration and cell body degeneration are separate 
phenomena (at least initially). Potentially, this provides insights into the human disorder SOD1-ALS 
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and the separate loss-of-function and gain-of-function effects arising from a single mutation, even 
though the mouse does not fully model human ALS (31).   
 Cellular and metabolic pathways may be common to both species but may have a different 
importance in each.  Mice lacking Hexa (hexosaminidase subunit alpha) were generated to model the 
lysosomal storage disorder Tay-Sachs disease, which in humans is caused by loss of HEXA function.  In 
finding out why the null mouse does not overtly model this deadly childhood disorder, researchers 
teased out an alternative metabolic pathway that is present in mice but of less importance in humans, 
although it could nevertheless still be used as a possible therapeutic route for treating this disease 
(32).  This highlights the important point that humans and mice have evolved to fill different niches 
and so major biochemical, metabolic and physiological pathways may be different between us. For 
example, compared to humans, mice have a higher specific metabolic rate (metabolic rate per gram 
of tissue) and, for example, larger deposits of brown fat that are essential for thermoregulation (33). 
Other differences include cell membranes that have more polyunsaturated fatty acids in mouse than 
in human (34); the different dietary requirements, for example, mice can synthesise vitamin C, 
whereas humans cannot (33); fundamental differences in the mouse and human immune systems (33) 
that must be taken into account as the connections between immunology and neurodegeneration are 
elucidated. 
 Genes themselves may be more important to one species than the other. For example, 
although we mostly share essential genes that are lethal if deleted, SOD1 is essential in humans but 
not in mice (35); Sod1 null mice survive, whereas no SOD1 null humans have been reported.  This is 
important when modeling SOD1-ALS, as the majority of mutations result in some loss of superoxide 
dismutase 1 activity, which may have a more severe outcome in human motor neurons than in mouse 
motor neurons (36).  
 Differences in gross morphology are also important for our modeling of human disease, for 
example, size is closely correlated with metabolic rate in mammals (33). With respect to the gut and 
the microbiome, the relative length of the small intestine to the colon is larger in mice than in humans, 
probably because the cecum is important for microbial fermentation of foods in mice (33, 37). Mice 
and humans have clear neuroanatomical differences in the brain and spinal cord, although less so in 
the peripheral nervous system.  In the brain, correspondence between human and mouse regions is 
largely characterised by histological staining patterns and the connections between regions, but there 
are many key differences. For example, the human brain has substantially more white matter than 
that of the mouse: the amount of white matter increases as a cubic function of the size of an animal 
because more axons are needed to innervate the body of larger animals (38). Also, some cell types 
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found in the human brain have not been detected in the mouse brain (39). Furthermore, we are largely 
visual animals, whereas mice rely more heavily on other sensory inputs, such as olfaction. 
 Lifespan is another important difference when considering mouse models of mid-life/old-age 
neurodegenerative diseases. For example, the widely-used mouse strain C57BL/6J typically lives for 
just over two years, compared to, say, people in Japan who have an average (male and female 
combined) life expectancy of greater than 83 years. A mouse succumbing to disease at one year of 
age may be in late middle-age (depending on the strain), whereas at three months of age (often the 
age when mice are studied) that animal may be still a young adult. Moreover, aging in mice does not 
necessarily reflect the same processes as in humans (40).  
 For both humans and mice, we need to carefully tease apart the effects of normal aging from 
the effects of neurodegeneration. For example, this is an issue when investigating AD that arises in 
individuals with Down’s syndrome, because premature aging is also part of the clinical picture of 
Down’s syndrome (41). Moreover, a related point for mouse models is that individual inbred mouse 
lines may have alleles that predispose them to progressive phenotypes as the mice age, such as retinal 
degeneration, hearing loss, and other defects, even before any mutation is placed onto these strains 
(42).  There are many apocryphal stories of researchers testing mice with visual cues, unaware that 
both littermate controls and mutant mice have vision loss. Therefore, we need to know about the 
normal aging characteristics of both mice and humans when investigating neurodegenerative 
phenotypes. 
 Undoubtedly one of the most difficult areas to tackle for neurodegeneration studies is that of 
behaviour.  Nevertheless, although behavioural changes are highly variable among people affected by 
neurodegenerative diseases, there are common patterns such as memory loss or disinhibition, 
depending on the disorder.  This is such a difficult area to appraise but is so important. 
 
  
8 
 
WHICH MUTATION, WHICH MOUSE MODEL?   
Whereas the majority of human neurodegenerative diseases are sporadic, meaning that we are all at 
risk (usually that risk increases with age), there are often rare familial monogenic forms of the disease 
that enable us to create animal models to study underlying mechanisms of pathogenesis. For example, 
up to 40% of FTD cases and 10% of ALS cases are due to mutations in single causative genes. Up to 5% 
of AD is inherited in an autosomal dominant manner due to mutations in one of three genes APP, 
presenilin 1 (PS1), and presenilin 2 (PS2). Approximately 15% of PD occurs in people with a family 
history of the disease and up to 2% of all PD is due to causative (usually dominant) mutations in single 
genes. Causative alleles can vary greatly in different populations: the G2019S mutation in Leucine-rich 
repeat kinase 2 (LLRK2) accounts for ~37% of familial PD in some Arab groups (43) but is rare in Taiwan 
(44).  At the other end of the spectrum, nearly 100% of Huntington’s disease (HD) arises from triplet 
repeat expansions in the HTT gene encoding the huntingtin protein. 
 Deciding which mutation to put into a mouse to model a specific neurodegenerative disease 
has often been a pragmatic choice of what is the fastest mutation to make, and what is likely to result 
in the most aggressive change found in humans, in order to have the best chance of producing a 
quantifiable phenotype in mouse. However, given the range of tools now available for genome 
engineering such as CRISPR/Cas, we can take a more considered approach to creating mouse models 
to answer specific questions about mechanism, without expecting a perfect mimic of human disease. 
Here, we discuss the range of genetic mouse models available. Mouse models created using 
recombinant adeno-associated viral (AAV) or lentiviral vectors, for example, are also giving new insight 
into disease mechanisms for diseases such as ALS  (45, 46). This is a rapidly developing field that has 
implications for studying mechanisms of neurodegeneration as well as providing insights for 
downstream gene therapy approaches; (47). Another area that will be extremely important for 
dissecting neurodegenerative disease mechanisms is the increasing use of human-mouse chimeric 
animals, in which specific cell types are human and can be studied in vivo in the mouse [for example, 
as when wildtype human cells are studied within the environment of the brain in a mouse model of 
the amyloid deposition found in AD (48)]. This research platform brings its own challenges including 
ethical issues, and is a rapidly expanding area that we touch on only briefly below. 
 
Mouse modeling: What is the question? 
There are a few key questions that reoccur with all neurodegenerative diseases. For example, specific 
proteins are usually deposited in aggregates in the brain – but is protein deposition a disease causing 
mechanism or a disease response mechanism, or both? Why do neurons die? Causative genes are 
usually ubiquitously expressed, so why do only specific types of neurons or synapses die, usually in a 
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well-described pattern? Does disease arise from loss-of-function or gain-of-function of the mutant 
protein, or both? What determines timing of symptom onset? Does a neuron die from mechanisms 
solely within that neuron (‘cell autonomous’) or do neighbouring cells play a role? How does the 
disease spread? What determines time to death? Why do these disorders progress from pre-
symptomatic to symptomatic to end-stage? Why does incidence tend to increase with aging? What 
pathways produce variation in severity (and penetrance of genetic disease) and are these pathways 
routes to therapeutic modulation? What is the connection between histopathological changes and 
altered behavior? What is the therapeutic window? Is neurodegenerative disease reversible?  
 To help answer these questions we can now create mouse models to order, with exquisite 
accuracy (Figure 2). These include knockin models where the human mutation is engineered into the 
mouse genome, genomically humanized mouse models, transgenic mice, chemically mutagenized 
mice, conditional mutant mice, inducible mutant mice, chromosome engineered mutant models, and 
transchromosomal mutant models, each giving different types of information about 
neurodegenerative processes (Figure 2). In creating a mouse model of neurodegeneration, we 
therefore need to consider ‘Which question are we trying to answer?’ and then ‘Which mouse model 
would best provide that answer?’ The two big caveats that need to be considered as we ask these 
questions are: (1) mouse models are not predictable and we need to make the mouse to learn about 
the phenotypic outcome (2) the ultimate mouse phenotype depends on genetic background and 
environment. 
 For research into early neurodegenerative processes, mice expressing disease genes at 
physiological levels may provide slowly progressing, prodromal disease phenotypes that do not reach 
end-stage within the lifespan of a mouse. However, this may not be helpful for trying to test 
therapeutics targeted to later stages of the disease, which is often when patients first come to the 
clinic. Developing biomarkers or predictors of disease (for example, blood biochemicals, neuroimaging 
modalities, behavioral changes) may require access to nervous system and other tissues across disease 
stages, using different mouse models to address diagnostic issues and to monitor therapeutic 
outcomes. Endophenotypes (characteristics associated with a disorder but not necessarily a direct 
outcome of that disorder) may help with such issues but need careful validation. Mouse models can 
also indicate whether disease is reversible even at late stage (49) or whether treating non-neuronal 
tissue is helpful. For example, we think of SMA as a neurological deficit but therapies derived from 
studying a genetic mouse model of severe SMA, now target the liver because pre-clinical studies of 
liver pathology showed efficacy in this model (50). 
 The most widely used models of dominant neurodegenerative disease are still transgenic mice 
created by injecting DNA into the pronucleus of a fertilized mouse egg. The DNA inserts randomly, 
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often creating additional unintended mutations such that multiple founder lines are required to 
exclude phenotypes arising from random insertion. The DNA also usually concatemerizes so the 
animal has multiple copies of the transgene and thus overexpresses the protein of interest. A study of 
40 well-cited transgenic strains, many of which are used in neurodegeneration research, showed that 
about half had mutations at the insertion site, although little phenotypic outcome appears to be 
associated with these insertional mutation events (51). Injected constructs are often cDNAs under the 
control of non-endogenous promotors that are not expressed with the same pattern as the 
endogenous gene and are only expressed as the splice isoform encoded by the cDNA.  Alternatively, 
Bacterial Artificial Chromosomes (BACs) may be injected into fertilized mouse eggs to create BAC 
transgenic mice.  These have the following advantages. BACs have large insert sizes (up to ~200kb) for 
genomic DNA that may include the entire promotor/exon/intron architecture of a single gene (or 
genes), thus, they may express the complete set of human splice isoforms. BACs also tend to integrate 
fewer than three copies hence ameliorating overexpression effects.  
 Transgenic mouse models expressing multiple copies of a mutant gene may show accelerated 
mid-life or late onset disease (if mutant protein levels and disease onset positively correlate), which is 
necessary for studying later stages of neurodegeneration.  However, phenotypes may arise as a result 
of overexpression per se, rather than being caused by the effects of the mutation within the transgene 
DNA, as exemplified by the SOD1G93A transgenic model of ALS (52). Nevertheless, this ALS mouse strain 
is used to model human SOD1-ALS disease. This has allowed scientists access to an animal model of 
rapidly progressing disease and enabled study of later neurodegenerative processes. However, it is 
particularly important that strains like the SOD1G93A transgenic mouse are compared to a transgenic 
mouse control overexpressing similar levels of the human wildtype protein, which in this case would 
be wildtype human SOD1 (53). 
 The utility of transgenic mice is exemplified by the field of prion disease research. Transgenic 
mice overexpressing a human prion protein were instrumental in showing that bovine spongiform 
encephalitis (BSE) could be transmitted between mammalian species (i.e. potentially to humans).  
Notably, had transgenic mice overexpressing the human prion protein not been used, this result would 
have been missed because the time course of the disease would have been longer than the lifespan 
of the mouse (54). 
 In terms of gene targeting, knockout mice have DNA sequences removed such that the 
targeted gene is no longer functional.  These mice may be conditional or inducible such that the gene 
either loses function in response to genetic triggers (conditional) or can be inducibly expressed under 
experimental conditions through hormone or drug administration, either by injection or addition to 
the drinking water. In addition to understanding gene function, these animals can be extremely helpful 
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for determining whether late stage neurodegeneration is reversible, by switching off the relevant gene 
mutation at specific time points (55).   
 Knockin mice have a sequence such as a mutation or mutant gene precisely targeted into their 
genome at a specific locus.  Sequences may have exogenous promotors and can be placed into ‘parking 
spots’ or ‘safe harbors’, such as the Rosa26 locus, which are safe places to insert foreign DNA without 
disrupting other genes. DNA sequences may also be targeted by homologous recombination or by 
CRISPR/Cas9 and other technologies into their orthologous mouse locus, such that they are expressed 
at physiological levels by the mouse gene promoter. Because gene expression is therefore lower than 
in transgenic models, knockin mice tend to have longer times to disease onset and a slower, less 
aggressive course of disease, which may give researchers access to early disease stages.  For example,  
a knockin mouse model of dominant ALS expresses the mutant protein VAPB (vesicle-associated 
membrane protein B/C) at physiological levels, and exhibits a much slower disease course than do 
transgenic animals overexpressing this protein (56). These knockin mice have dysfunctional motor 
neurons but no signs of motor neuron loss.  Despite the lack of motor neuron death in this model, it 
gives us access to early disease processes and potentially to biomarkers, which are urgently needed 
for many human neurodegenerative diseases. Equally, mouse models of PD may not give the full 
human clinical picture, but can give access to the prodromal syndrome including behavioral 
abnormalities (57), although it can be difficult to tease out repair and compensation responses from 
true disease processes found in humans. 
 Knockin mouse models are particularly important if the gene of interest is dose-sensitive, i.e. 
more than the normal two copies gives rise to a phenotype that is not necessarily related to the 
disease under study.  For example, point mutations in the FUS gene (fused in sarcoma) can cause ALS.  
As FUS is a dose-sensitive gene, transgenic FUS mice do not model FUS-ALS well, whereas knockin 
models expressing pathogenic FUS mutations at physiological levels are excellent models of ALS, giving 
access to early stage disease processes (55, 58). OtherALS genes such as C9orf72, or TARDBP which 
encodes the TDP-43 protein are also exquisitely dose sensitive(56, 59-62). 
  Another class of knockin mice are the genomically humanized models, in which either whole 
genes in the mouse genome are replaced with human genes (63, 64), or key mouse amino acid 
residues are targeted by knock in constructs and changed into human amino acids in the hope of 
producing more accurate phenotypes of human disease. These include the APPNL-F and APPNL-FG models 
of amyloid deposition (65) in which critical amino acids have been changed from mouse to human 
residues in the mouse APP protein, thus making amyloid-β (Aβ) fragments generated from APP more 
prone to aggregation.  
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 Mutant mouse models can be generated with random mutations in the genome, such as those 
arising from chemical mutagenesis (66), which may give unexpected insights into gene dysfunction at 
physiological levels. For example, a chemically induced point mutation that turned out to be within 
the microRNA, miR-96, was shown to give rise to progressive hearing loss in mice (67)  and this 
mutation was also found in humans with non-syndromic progressive hearing loss (68). Other types of 
mouse model include those created by chromosome engineering, which enables massive blocks of 
DNA  to be moved around the genome or the deletion or duplication of big genomic regions. This 
allows us to model, for example, chromosomal full or partial aneuploidy (6, 69) or large-scale copy 
number variation (70).  
 A different type of model is provided by chimeric mice, which are made from two different 
cell lines and can be extremely helpful in dissecting cell autonomous and non-autonomous processes. 
For example, human pluripotent stem cell-derived cortical neuronal precursor cells derived from 
unaffected individuals have been transplanted into the brain of both a mouse model of AD and 
wildtype animals. Notably, only the human neurons in the AD mice  showed signs of 
neurodegeneration indicating that that human neurons respond to Aβ pathology differently from 
mouse neurons, in vivo, and the neurodegeneration is non-cell autonomous; the authors also showed 
neuronal death due to Aβ deposition can be dissociated from tau tangle formation (48).  In another 
example, chimeric mice with motor neurons expressing either wildtype or mutant SOD1 (causative for 
ALS) provided strong evidence that ALS is a non-cell autonomous disorder (71).  Somatic mutation in 
which DNA changes in non-germ cells, such as neurons, are causal for neurodegeneration, can be 
modelled by conventional transgenic mice (72), andother types of mice with mosaic expression of key 
genes (73). It is likely that the use of chimeric mice to model neurodegeneration, for example, mice 
with a human immune system or specific human neurons, will increase greatly in the future. 
 Another advantage of working with mouse models to understand neurodegeneration is the 
ability to cross independent models and to study the double mutant progeny to tease out disease 
networks. Examples include a recent study of demyelinating and axonal neuropathy with specific 
genes that modify these phenotypes in mouse models of Charcot-Marie-Tooth disease (74), and a 
study of the effects of ApoE4 on tau-mediated neurodegeneration (75), and a study crossing a  model 
of amyloid deposition and one of Down syndrome to try to determine why Down syndrome gives rise 
to early onset AD (76) . Similarly, such classical genetic crosses allow the uncovering of new genetic 
interactions, such as that between mutant SOD1 in ALS models and the cytoplasmic dynein heavy 
chain (77-79). 
 Clearly, one single mouse model for any given disease is unlikely to provide all of the outcomes 
needed to understand both the underlying early-stage and late-stage molecular mechanisms and to 
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develop therapies and biomarkers. We need a tailored range of different animal models to address 
different questions about disease pathogenesis and treatment, and fortunately we are now in a 
position to produce the mice we need. 
 
THE IMPORTANCE OF VARIABILITY  
Genetic mouse models enable us to study phenotype in a highly controlled system under well 
controlled conditions. They can help to tease out how individual variation arises and how it impacts 
disease, but only if rigorous statistical and unbiased  blinded approaches to analysis are taken (80, 81).  
This variation may highlight key cellular pathways, as exemplified in human GWAS, and it provides a 
potential basis for dissecting individual responses to disease processes and therapeutics. However, as 
with humans, we still understand comparatively little of what causes variation in individual mice.
  
Age, gender and genetic background are well-known and significant sources of variation in 
mouse studies. For example, a single well-defined mutation can result in markedly different 
phenotypes when bred onto different inbred mouse lines, which have homogeneous (within the 
inbred line) but different (between inbred lines) genetic backgrounds (60, 82). This includes 
‘collaborative cross’ mice, and ‘recombinant inbred’ mice,  designed to have known variation in their 
genetic background to help map the genetic components of complex gene-environment interactions 
(83, 84).  Not surprisingly, therefore, those breeding mouse lines go to great lengths to try and 
maintain a standard background and avoid genetic drift over time (85). In working with different sub-
strains of individual inbred lines, we may have expectations that sub-strains used in different 
laboratories will be similar to each other, whereas in fact they can be markedly different. For example, 
the widely used C57BL/6J and C57BL/6N sub-strains have some notable phenotypic differences such 
as reduced motor performance in the C57BL /6N compared to the C57BL/6J sub-strain (86).  
 Genetic background effects can in fact give great biological insight as this common source of 
variation can be used to help identify modifier loci (87). For example, a modifier locus for human 
Dravet’s syndrome (a severe, infant-onset epileptic encephalopathy) was identified using the strain-
dependent epilepsy phenotype of a mouse carrying a Scn1a (sodium voltage-gated channel subunit 
1) mutation (88). Another example comes from studies of the Cacna1c gene encoding calcium voltage-
gated channel subunit 1C and the Tcf7l2 gene encoding transcription factor 7 like 2, which have 
been implicated in human psychiatric disorders and in type 2 diabetes, respectively. Crosses of null 
mutations in these genes onto 30 different inbred lines showed that opposite effects from the same 
allele could occur depending on the genetic background, and that sex could also have a marked effect 
on phenotype (89). Thus, if we confine ourselves to studying one inbred line, or one sex, we may miss 
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the panoply of variation arising from a single mutation. Rather surprisingly, the genetic background in 
a mouse cross can also include ’inert’ control elements such as the tetracycline transactivator, which 
in theory only exert an effect when activated, but in practice may independently affect phenotype 
(90).   
 Other sources of variation such as parent-of-origin effects (when phenotype from an allele 
depends on which parent contributed the allele)(91) (which may warrant phenotyping wildtype 
offspring of mutant mice) and contributions from transgenerational inheritance (92, 93) may be 
important sources of variation for some phenotypes. Similarly, even when closely defined hybrid lines 
are used in highly controlled environments, litter-of-origin effects (i.e. the phenotype depends on 
which litter a mouse comes from) may arise. Thus, mice from the same litters should be distributed 
across experimental cages, as demonstrated in a carefully controlled therapeutic preclinical trial in 
mice modeling certain aspects of HD; this study noted sources of variability such as maternal 
nutritional status which may result in pups from the same litter having similar characteristics, 
regardless of genotype, and in fact the authors saw a modest effect of litter of origin on a behavioural 
phenotype of their mice  (94). 
 It is important to identify and understand the many other sources of phenotypic variation so 
that we can fully characterize our animals, and thus better understand the variation in human health 
and disease (95). This may be crucial for understanding gene interactions and also gene-environment 
interactions, both of which can exert huge influences on disease etiology and progression. Here, we 
briefly discuss some of the conditions leading to phenotypic variability between studies. 
 
Life history, well-being and stress 
Life history is an important determinant of disease, for a mouse and for a human. For example, the 
level of adversity during development biases protective stress or anxiety responses in order to better 
adapt an organism to the environment into which it was born (resilience), but then these same 
responses persist into adulthood (96-98). Notably, this may not always be helpful later in life if there 
is a mismatch between the developmental and adult environments.  Mice, like humans, are affected 
by early life trauma, which can alter brain structure, produce epigenetic and genomic effects and lead 
to neuropsychiatric phenotypes later in life (99-104). Stress can also influence the in utero 
environment such as when effects of maternal inflammatory responses lead to brain and behaviour 
abnormalities in offspring (105) or when prenatal stress disrupts the maternal vaginal microbiome 
leading to lasting effects on the gut and hypothalamus of male offspring (106) .  
 Indeed, stress is a hugely important determinant of pathology and behavioral sequelae in 
neurodegenerative disorders. Stress and the hypothalamic-pituitary-adrenal (HPA) axis are key 
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determinants of the concentrations of circulating corticosteroid hormones, which can have powerful 
effects on neurodegenerative phenotypes. For example, stress, either from chronic isolation or as the 
result of an acute challenge, can lead to increased Aβ peptide in brain interstitial fluid in a transgenic 
mouse model of Aβ deposition used to study AD (101). 
 
Social interactions play a role in mouse and human well-being, and can markedly affect 
phenotypes.  Single housing of social animals such as mice causes stress and aberrant behaviors (107). 
Furthermore, social hierarchies and dominant/submissive relationships may have a profound impact 
on mouse well-being and so, for example, the population density of a cage may affect the phenotype 
(108). Likewise, human relationships are important for outcomes in neurodegeneration. For example, 
in an ALS patient cohort, being married was associated with an 8-month median longer survival time 
compared to single individuals (109).  Interestingly, it now appears that the genetic status of those 
surrounding an individual may also be important for its well-being. Notably, in mice, several traits ---
from wound healing to anxiety ---are affected by the genotype of cage mates (110). 
 Ambient temperature is a source of variability we rarely consider because mice are generally 
housed at temperatures of between 20-26 oC. However, this may be too cold, as mice have activated 
thermogenesis at these temperatures to maintain their normal body temperature. This mild chronic 
cold stress affects tumor formation and metastasis, potentially confounding our understanding of 
these processes. This may also be true for neurodegenerative mechanisms (111) and for metabolic 
pathways (112). Notably, some researchers, including those engaged in therapeutics studies, are 
moving to keep their mice, inbred strains or outbred strains, in environments that as closely as 
possible mimic those of wild mice (113).   
 
Circadian rhythms and sleep 
Circadian rhythms can affect experimental and pathological outcomes in neurodegeneration research 
(114). In fact, the authors collect tissue samples only at specific times of the day to avoid variations in 
gene expression arising from circadian rhythms; for example, normal daily cycles in body temperature 
affect alternative splicing of transcripts (115). Similarly, behavioral testing is usually carried out at the 
same time of day within an experiment in order to minimize variability.  However, as a consequence, 
we may miss phenotypic variation across the 24-hour cycle. This may be particularly important as 
disruption of normal circadian rhythms can impact biochemical pathways underlying neuropathology 
and the expression of their behavioral sequelae (116). Moreover, it is notable that many laboratories 
conduct behavioural tests during the animals’ subjective day, despite the fact that the species is 
nocturnal. 
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 Related to circadian effects, is the importance of sleep and sleep disturbance in the 
development of neurodegenerative phenotypes. For example, sleep plays a critical role in the 
clearance of Aβ from the brain (117). Thus, sleep deprivation and sleep disruption may impact Aβ 
deposition and exacerbate disease phenotypes and progression by affecting Aβ removal from the 
brain (118). Moreover, sleep disruption per se may also directly exacerbate cognitive impairments 
arising from neuropathological changes, similar to its putative effects in neuropsychiatric conditions 
(119). 
 
Exercise and environmental enrichment 
Physical exercise plays an important role in modulating brain function. Exercise results in the release 
of trophic factors including brain-derived neurotrophic factor (BDNF) (120), and promotes 
neurogenesis in the dentate gyrus of the hippocampus (121-123), a brain area implicated in 
neurodegeneration and its behavioral sequelae. Exercise, such as voluntary wheel running in mice, 
enhances both glymphatic influxand improves cognitive performance on behavioural tasks(123, 124). 
Environmental enrichment can also have an enormous impact on the development of behavioral and 
histopathologial trajectories in mouse models of neurodegenerative disease. For example, the onset 
of cerebral volume reduction and motor disorders are delayed in an HD mouse model if the animals 
are exposed to a stimulating environment from four weeks of age (125, 126). This may parallel the 
concept of cognitive reserve, such that people who frequently perform cognitively demanding tasks 
may be less likely to suffer from deterioration of brain function (127). 
 
Diet, the microbiome and inflammation 
An advantage of working with mice is to be able to study the effects of diet on any given phenotype 
(128). However, often scientists may not even be aware of any variation in mouse diet. Many mouse 
chows contain soy and so may result in a relatively large intake of phytoestrogens, potentially 
influencing disease outcomes such as anxiety or pain. Exposure to phytoestrogens in utero also has 
effects on disease outcomes in adulthood. However, the amount of soy and therefore phytoestrogens 
can vary between batches of chow, thus potentially adding to variability in phenotypes (129). This may 
be relevant to modeling disorders such as ALS in which estrogen may have a protective effect (130).   
 Alterations in the gut microbiome, whether derived from diet or otherwise, can also have a 
great influence on biochemical, neural and behavioral phenotypes (131, 132), and lab mice have a gut 
microbiome that is notably different from their wild relatives (133). Strikingly, transplant of gut 
bacteria from PD patients into transgenic mice overexpressing -synuclein exacerbated motor 
deficits, microglia activation and pathology, an effect which, in turn, could be ameliorated by antibiotic 
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treatment (134). Recently, a species of Lactobacillus has been found to reverse the social deficits, akin 
to human autism spectrum disorder, found in progeny of mothers fed with high-fat diet; intriguingly, 
these effects act via the vagus nerve, and not by restoring the composition of the offsprings’ gut 
microbiome (135). Efforts are now underway to define the effects of the wild mouse gut microbiota 
in promoting host fitness (133). 
 The overall health status of the mouse colony can greatly affect the cellular components of 
the innate and adaptive immune systems, which may affect phenotypes in mouse models (136). CNS 
inflammation has long been established as important in the progression of neurodegenerative 
disorders (137). Recently, it has been found that systemic inflammation also plays a key role (138). 
The adaptive pathways by which signals of systemic inflammation are communicated to the brain have 
now been well described, and it is becoming increasingly clear that excessive or prolonged activation 
of these pathways is detrimental to the brain (105), and can exacerbate neurodegenerative 
conditions. Thus, health status may be an important determinant of the rate of progression of 
pathology in a given mouse model of neurodegenerative conditions. Indeed, this may relate to a much 
bigger story about how the health status of human subjects impacts disease etiology and progression. 
In particular, infection and inflammation may be key drivers of disease processes, including those 
underlying neurodegenerative disease (73, 139).  
 
Making sense of behavior 
A further major source of variation across laboratories and across studies comes from the behavioral 
phenotyping of mice. Often the use of different behavioral tasks and different tests protocols in 
different laboratories means that researchers are not actually assessing the same behavioral 
processes in their mouse studies, and hence different results can be obtained. Even small differences 
in experimental protocol (such as the amount or nature of any pretraining, duration or nature of 
stimuli, inter-trial interval, motivational state) can have a major influence on the way rodents might 
solve a particular task and hence the sensitivity of the animals to a given experimental manipulation. 
This reflects the multiple memory mechanisms and cognitive processes underlying complex behaviors 
in both rodents and humans. Again, understanding the sources of this variability across studies, in 
terms of behavioural outcomes, may shed light on disease processes. 
 A key related question when using genetically modified mouse models of neurodegenerative 
disorders is whether the behavior we are studying in our rodents is accurately modeling the 
appropriate behavior in humans? Therefore, it is essential to identify the psychological process that is 
disrupted in a given mouse model, to determine whether this is the same psychological process that 
underlies impairment in human patients. A clear understanding of these psychological processes will 
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also greatly aid in identifying the underlying neural circuits and mechanisms that are affected in the 
animal model. Importantly, this requires the characterization of the mouse model across several 
behavioral tests, which allows the precise nature of the impairment to be inferred by comparing what 
the mouse can and cannot do. It is not possible to determine the key psychological process that is 
disrupted in a disease model from studying mice in just a single task. 
 In a number of situations, classical rodent assays of cognitive behavior may not always model 
the human cognitive process as intended (Figure 3). For example, do deficits in Morris watermaze 
performance in mouse models of neurodegeneration always indicate memory impairment (140)? Is 
working memory as studied in rodents undertaking a win-shift maze task (for example, the radial maze 
or T-maze task) really the equivalent of working memory in humans as studied, for example, in the N-
back task or the digit span task (141)? Instead of using working memory, rodents may often solve 
these tasks using familiarity judgements based on short-term habituation processes (141).  Is 
contextual fear conditioning in mice measuring episodic memory or conditioned anxiety (a change in 
emotional state).? There are also a number of potential problems with this test, including generic 
issues with interpreting freezing data in animals that exhibit marked locomotor hyperactivity, 
including many mouse models of neurodegenerative disease.  Examples from basic science 
experiments have highlighted these issues but the questions raised from these studies also likely apply 
to tests with neurodegenerative mouse models. This demonstrates the importance of extending 
behavioral tests to provide a more comprehensive and precise description of any cognitive and 
psychological deficits in the animal model.  
 In the Morris watermaze swim test, for example,  it is imperative to include the appropriate 
control tasks that are well matched in terms of sensorimotor and motivational task demands (visual 
acuity, emotionality, stress, swim time, difficulty, etc.). In addition, a battery of spatial memory tests 
also needs to be included to allow the generality of any findings from the watermaze swim test to be 
ascertained under different behavioral conditions that are unaffected by performance factors like 
thigmotaxis (continually swimming close to the side wall of the pool) and floating behavior. Both of 
these behaviors present confounds in watermaze studies conducted in mouse models of 
neurodegeneration (140). The distance that the platform is located from the side wall of the pool may 
thus be an important experimental variable in such studies (142). If a watermaze deficit in a mouse 
model of neurodegeneration is due to thigmotaxis (possibly as the result of altered anxiety), any drug 
treatment developed from such an assay may be unlikely to remedy cognitive symptoms in patients. 
Conversely, however, increased thigmotaxis or enhanced floating behavior likely reflects important 
behavioral responses to a given aversive situation. Understanding these behaviors and the 
contribution that a particular genetic change or its neuropathological sequelae make to these 
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phenotypes, may provide important information about emotionality phenotypes (such as depression, 
anxiety) that can occur in neurodegenerative conditions in human patients.  
 
Phenotyping is a group activity 
Importantly, the best way of working with mice, which also likely involves using the fewest animals, is 
to work collaboratively with scientists with expertise in different areas---from genetics to 
physiology/endocrinology, from transcriptomics to developmental/behavioral biology, from protein 
chemistry and neuroimaging to immunology---in concert with clinical experts for each 
neurodegenerative disease. Multidisciplinary teams enable us to maximise what we learn from each 
model including pleiotropic effects (separating these from co-morbidities, for example), and help us 
to avoid maintaining too narrow a focus, for example, on just one specific cell type. Each mouse 
mutant should undergo broad phenotyping of the sort provided by the International Mouse 
Phenotyping Consortium (81), as well as in-depth investigations into disease mechanisms by disease 
specialists. 
   Metabolomic studies provide a good example of why studying neurodegeneration should not 
only be the work of neuroscientists. One of the most distressing aspects of ALS and HD is weight loss 
and this may correlate with poor clinical outcome. Furthermore, low body mass index is thought to be 
a risk factor for ALS (143). In ALS, we know there are lipid disturbances in both humans and mouse 
models but why these arise remains unknown. This could turn out to be an important avenue of 
research for those developing disease-modifying treatments.  
 
TRANSLATION: THE ELUSIVE FRONTIER   
Despite the hundreds of mouse models of human neurodegenerative disease, we still have no cure 
for any major form of neurodegeneration and only extremely limited treatments for just a handful of 
these diseases. Many insightful articles have been written about moving forward from mouse studies 
of disease mechanism and the difficulties of translating therapies that modulate disease in mice to 
successful human clinical trials [for example, see (27, 125-128)]. Here, we suggest that variability in 
both mouse and human may be an important factor underlying current translation failures, but also 
may be a source of insight into disease mechanisms.   
What is translation?  
The translation phrase “from bench to bedside” encompasses two separate processes: (1) the 
discovery of mechanisms of disease pathogenesis, and (2) the development of new therapies and their 
testing in clinical trials. In our view, mouse models have great utility for dissecting biological processes, 
but so far have not proven particularly useful or practical for producing treatments that work in 
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humans, with a few notable exceptions including the success of antisense oligonucleotide therapies 
for treating SMA) (148).  Currently, therefore, the major and proven utility of mouse models lies in 
identifying disease mechanisms. Their potential utility (or lack thereof) as drug screening tools may 
only become apparent once we have a better understanding of both pathomechanisms and the 
reasons why current attempts at translation have so often failed. We argue that the answer to the 
latter question may partly lie within our appreciation of the variability in our mouse studies and also 
the great variability within the human clinical population. 
 
From mouse and mechanism to medicine 
In biomedical studies, we generally only look at a snapshot of disease. For technical or financial 
reasons, we study genetic mutations in one or two inbred mouse lines only, or worse yet, on ill-defined 
outbred mouse lines that are usually a lot more inbred than expected (149) [although outbred lines 
certainly have their uses (150), and abuses (151)]. We tend to study single gene mutations even 
though most human disease is a mix of genes plus environment, and even rare monogenic diseases 
may show synergistic effects between unrelated genetic loci (152).  
  As scientists, our cultural viewpoint is to minimise variation within 
our studies in order to maximise our chances of identifying significant differences between 
experimental and control conditions. To this end, we generate genetically modified mice on 
homogeneous genetic backgrounds and maintain these animals under constant environmental 
conditions. It follows that any important discoveries arising from these animal studies, particularly 
with respect to therapeutics that modulate biochemical pathways and networks, may only be relevant 
to a limited subgroup of the clinical population. 
  It is not surprising, therefore, that when attempts are made to 
translate findings in animal models to the much more heterogeneous human clinical population 
(which varies in terms of age, gender, genetic background, environment, and life history), these 
attempts have failed consistently. Put another way, the homogeneity of approach that benefits 
reproducibility and increases statistical power in preclinical studies (and yet that is still remarkably 
difficult to carry out in mice) may come at the cost of reducing generalizabilty when it comes to 
translation of therapeutics from mouse to human  (145). This issue is not exclusive to animal models 
of neurodegeneration, but instead reflects a general problem in making the crucial step between pre-
clinical studies in animals and clinical trials for many human disorders, as has been highlighted in the 
stroke field (145, 153) as well as in neurodegeneration studies (154). Researchers have made 
suggestions for improving this process, such as performing mouse studies across several independent 
laboratories in order to mimic multi-center clinical trials in humans. Nevertheless, at the heart of this 
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issue remain both the inherent variability of pre-clinical mouse studies and, possibly even more 
important, the pronounced variability of human clinical patient populations. Crucially, therefore, 
embracing rather than rejecting variability in our mouse studies, and then understanding both its 
sources and its underlying mechanisms, could be of great benefit for successful translation to clinical 
patient sub-groups. Moreover, it seems likely that questions regarding the utility (or otherwise) of 
mouse models for determining pathomechanisms relevant to human neurodegenerative conditions, 
and ultimately as drug screening tools, can only be properly answered once we have addressed this 
central issue of variability. 
 Although currently we have few treatments for human neurodegeneration, and a relatively 
limited understanding of the mechanisms underlying neuronal death, we are also racing into a new 
era of personalised medicine. By working with the appropriate mouse models to address specific 
questions and by examining causes of variation in these models, we can help to identify diverse 
mechanisms of neuronal dysfunction and neuronal death. Variation may be particularly important for 
neurodegenerative disorders given the heterogeneous nature of many of these conditions, and given 
the current drive to identify biomarkers allowing stratification of patient subgroups, precision 
medicine, early diagnosis and response to therapeutic intervention.  
 It is impossible to standardize all experimental conditions across laboratories, but instead we 
need to recognise variation and use it as a source of insight. Variation has hitherto been seen as a 
problem and something that should be diminished and reduced at all costs. Here, we suggest that 
variation could be an opportunity that may allow us to understand and identify disease mechanisms 
and risk factors, and at the same time elucidate treatment strategies, on an individual by individual 
basis. Indeed, embracing and understanding variation may be of great benefit for translation. Of 
course, identifying the sources of variation will not be straightforward but, nevertheless, we suggest 
the following agenda for working with mouse models of neurodegeneration.  
We believe mouse models should be studied in response to a specific need, for example, 
animals with slow disease progression and relatively mild phenotypes would be best used for 
understanding early disease pathogenesis, but these animals may not be useful for clinical trials of 
therapeutics developed for treating late stage human disease (Figure 2). Both scientists and funding 
agencies should take a more sophisticated approach to each mouse model and not expect complete 
recapitulation of the human disease. Mouse models often may be better suited as tools for 
understanding the role of a specific gene or protein, or a specific aspect of the disease process, rather 
than as primary drug-screening tools.   
To capture how variation arises, we need considerably more detail than is often provided in 
research papers (95). In an attempt to ensure mouse phenotypes are fully defined in the literature, 
22 
 
the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research 
(NC3Rs) introduced a checklist of information required for any paper describing animal research called 
the ‘ARRIVE guidelines’ (Animal Research: Reporting of In Vivo Experiments) (146). Undertaking animal 
studies in accordance with the ARRIVE guidelines should mean some sources of variability are clearly 
reported (146), and so we can begin to understand their effects on mouse phenotypes. Furthermore, 
peer review should be rigorous to ensure accurate reporting of such crucial experimental details. 
However, more than anything, as a scientific community we need to change our attitude to the 
variability in our data. We need to create long-term metadata repositories in which data are deposited 
and made available to the wider community for critical analysis and further phenotypic screening.  
New approaches to working with mice are on their way. For example, Home Cage analysis 
enables us to capture aspects of behavior not seen when humans are around (155). New informatics 
approaches including machine learning could help us to find new phenotypes from the immense 
amount of data generated by Home Cage analysis. Developing ontologies for human-mouse 
phenotypes, in combination with new imaging and computational methods to help cross-reference 
between mouse and human data sets, will greatly enrich our understanding of human (and mouse) 
biology and will help to elucidate neurodegenerative processes, but only if we also take variation into 
account.   
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Fig. 1. Examples of differences in human and mouse genetic loci that may affect how we model 
neurodegeneration. 
Humans and mice are separated by only 75 million years of evolution.  Genetic differences that give 
rise to neurodegeneration in humans but are not found in mice, include human or primate specific 
repeat sequences that may mutate a gene giving a human disease such as the ‘SVA’ repeats (red box) 
that have inserted into the intron of the FUKUTIN and the TAF1 genes, giving Fukuyama muscular 
dystrophy and X-linked Dystonia Parkinsonism, respectively (exons shown as grey boxes) (23, 24). 
Gene regulation may be different, for example, as in OSTEOCRIN which is expressed in the human but 
not mouse nervous system because primates have acquired an enhancer (red box) leading to neuronal 
expression (21). Splicing patterns may be different between human and mouse as occurs in normal 
expression of the TAU mRNA and protein (20) or abnormal expression of STATHMIN2 in ALS (26).  Gene 
copy number can be different between the two species, as with the single Smn gene found in mouse 
and its paralogous SMN1 and SMN2 genes in humans that when mutated give rise to SMA (11). Mouse 
genes are arranged over 19 autosomes and 2 sex chromosomes, and human genes lie within 22 
autosomes and 2 sex chromosomes, such that the most common genetic form of cognitive disability, 
Down’s syndrome which arises from trisomy 21, must be modelled either by creating an animal with 
the human (7) chromosome  or by chromosome engineering duplications in the three mouse 
chromosomes (10, 17, 16) with regions of homology to human chromosome 21 (8).  At a population 
level we usually study inbred strains of mice, which are genetically homogenous, compared with 
human populations which are genetically diverse.  
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Fig. 3. Behavioral tests for mouse models of neurodegeneration.  
(A) In the Morris watermaze test (top panel) rodents are trained to find a hidden escape platform that 
is submerged 1-2 cm below the surface of the water (left) but that remains in the same spatial location 
relative to external cues. There are difficulties associated with testing mice in this watermaze task 
such as thigmotaxis, floating behavior and fatigue following prolonged swim times, all of which are 
often more pronounced in genetically modified animals. The question is whether impairments in 
watermaze performance in some mouse models of neurodegenerative disorders genuinely reflect 
deficits in learning and memory that the water maze test is supposed to measure. (B) Spatial working 
memory in rodents is tested using a radial maze or T-maze, but these tests may not equate to tests 
used in humans to measure working memory such as the N-back or digit span tasks. In the T-maze 
task, during the sample run (left ) the rodent is forced into one of the two arms of the maze to obtain 
a food reward. After a short delay, the animal is then given a choice between both arms of the maze 
and must go to the previously unvisited arm to gain a second reward (choice run; right). (C) Contextual 
fear conditioning in rodents is often used to test hippocampus-dependent, rapid, one trial, episodic-
like memory.  In this task, rodents are placed in a novel chamber and receive a mild footshock. The 
rodent is then later returned to the chamber and the amount of freezing behavior that the animal 
exhibits is taken as a measure of how much it has learned about the context-shock association. 
 
